Ustekinumab Intravenous (Stelara®, Imuldosa®, Otulfi™, Pyzchiva®, Selarsdi™, Steqeyma™ , Wezlana™, Yesintek™ , ustekinumab, ustekinumab-ttwe)

Covers a single weight‑based IV induction dose of ustekinumab for adults (≥18) with moderately‑to‑severely active Crohn’s disease or ulcerative colitis, excludes patients <18 and does not authorize maintenance/subsequent dosing (approval = one dose/30 days). Approval requires use as induction, prescribing or consultation by a gastroenterologist, documentation of diagnosis, age, weight and safety criteria, and for Crohn’s disease documentation of one prior systemic agent trial (mesalamine does not count) OR corticosteroid use/current use/contraindication OR prior ileocolonic resection OR enterocutaneous/rectovaginal fistula.

"adult patients with moderately to severely active Crohn's disease"

Sign up to see full coverage criteria, indications, and limitations.